BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DA-5218 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DA-5218\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07229534-432@assetmemo.bio
DTSTAMP:20261121T005403Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:DA-5218: Phase 4 readout est. (NCT07229534)
DESCRIPTION:DA-5218\, phase 4\, Type 2 Diabetes.\nStudy: Clinical Trial to 
 Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabet
 es\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/da-5218#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07229534
URL:https://assetmemo.bio/drug/da-5218#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
